Abstract
As cancer therapies advance and long-term survival rates improve, many adolescents and young adults face a future of treatment-related infertility. The National Cancer Institute estimates that 250,000 current cancer survivors are women of reproductive age, including adolescents and young adults aged 20–30 years old. It is estimated that by the year 2026, in the United States, the population of cancer survivors overall will increase to 20.3 million, with 10.3 million being female survivors and 900,000 of those being in the reproductive age range. Furthermore, there is a trend toward delayed childbearing, resulting in women facing a cancer diagnosis in their latter reproductive years with subsequent gonadotoxic treatments that can lead to premature ovarian failure. Data shows that cancer-related infertility is distressing to women, with nearly 50% of surveyed survivors finding it “significantly burdensome” that they may never have a child in the future due to their cancer treatment. The American Society of Clinical Oncology (ASCO) published updated guidelines in 2018 to encourage healthcare providers to discuss the potential for treatment-related infertility for those receiving gonadotoxic therapies and provide prompt, pretreatment referral to reproductive specialists for individuals who are interested in or ambivalent about fertility preservation; reproductive specialists can further facilitate discussion of fertility preservation options and help patient’s make well-informed decisions—engaging patients in their treatment plan in this manner not only improves long-term quality of life but also decreases decisional regret moving forward. Despite clear recommendations, many patient and physician barriers exist, preventing broad implementation of personalized oncofertility counseling for women who are newly diagnosed with cancer. Often, patient fears about cancer recurrence or worsening of disease prevents them from even broaching discussion of the topic with their healthcare provider team. Recent data shows that for women with a variety of cancer types (including breast, gynecologic, and hematologic malignancies) undergoing controlled ovarian hyperstimulation (COH), in both a random start or cycle-specific start fashion for oocyte and/or embryo cryopreservation, the approximate 2 week delay to initiation of cancer therapy is neither clinically significant nor impactful on long-term outcomes and risk of recurrence. This data can be used to calm patient fears as well as healthcare provider misconceptions about the timing and safety of fertility preservation so that patients can take advantage of the most effective options that are available to them. Various tools exist for fertility preservation counseling, including decision aids and decision trees. Patients may also benefit from the availability of a patient navigator to initiate discussions about fertility and coordinate appointments with fertility specialists during the uniquely stressful short time period between diagnosis and treatment initiation. While oocyte and embryo cryopreservation through COH remain first-line therapies, ovarian transposition and ovarian tissue cryopreservation (OTC) are also options for patients, specifically for those who receive pelvic radiation and prepubertal girls. Ultimately, some survivors may not choose to pursue fertility preservation options for various reasons (i.e., urgency of treatment, financial constraints, and moral considerations) and others may not desire future pregnancy at the time of diagnosis. It is important to make patients aware of other strategies for family planning, including adoption, gestational surrogacy, and use of donor gametes/embryos. With more survivors living into their reproductive years and beyond, fertility preservation counseling for women of reproductive age is not only ideal but also a cornerstone of comprehensive cancer care.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
American Cancer Society. Cancer facts and figures 2019. Atlanta: American Cancer Society; 2019.
Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA, editors. SEER cancer statistics review, 1975–2010. Bethesda, MD: National Cancer Institute; 2013. https://seer.cancer.gov/archive/csr/1975_2010. based on November 2012 SEER data submission, posted to the SEER web site.
Miller KD, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019; https://doi.org/10.3322/caac.21565.
National Cancer Institute. Adolescents and young adults with cancer. Updated 2018. https://www.cancer.gov/types/aya.
Keegan THM, et al. Comparison of cancer survival trends in the United States of adolescents and young adults with those in children and older adults. Cancer. 2016;122(7):1029–37.
National Cancer Institute. Cancer statistics. Updated 2018. https://www.cancer.gov/about-cancer/understanding/statistics.
Schover L. Motivation for parenthood after cancer: a review. J Natl Cancer Inst. 2005;2005(34):2–5.
American Cancer Society. When adolescents and young adults get cancer. Atlanta: American Cancer Society; 2018.
American Cancer Society. Adolescent and young adult cancer survival rates increase when re-evaluated. Atlanta: American Cancer Society; 2018.
Woodard TL, et al. The pathways fertility preservation decision aid website for women with cancer: development and field testing. J Cancer Surviv. 2018;12(1):101–14.
Canada AL, Schover LR. The psychosocial impact of interrupted childbearing in long-term female cancer survivors. Psycho-Oncology. 2012;21(2):134–43.
Levine J. Gonadotoxicity of cancer therapies in pediatric and reproductive-age females: Chapter 1. In: Gracia C, Woodruff TK, editors. Oncofertility medical practice: clinical issues and implementation. New York: Springer Science; 2012.
Kim SY, et al. Toward precision medicine for preserving fertility in cancer patients: existing and emerging fertility preservation options for women. J Gynecol Oncol. 2016;27(2):e22.
Biedka M, et al. Fertility impairment in radiotherapy. Contemp Oncol (Pozn). 2016;20(3):199–204.
Oktay K, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018;14(6):381–5.
Lee SJ, et al. American Society of Clinical Oncology recommendations on fertility preservation in patients. J Clin Oncol. 2006;24(18):2917–31.
Ethics Committee of the American Society for Reproductive Medicine. Fertility preservation and reproduction in patients facing gonadotoxic therapies: an Ethics Committee opinion. Fertil Steril. 2018;110(3):380–6.
Geneva Foundation for Medical Education and Research. Obstetric and gynecology guidelines: fertility preservation resources. 2018.
Benedict C, et al. Fertility issues in adolescent and young adult cancer survivors. J Adolesc Young Adult Oncol. 2016;5(1):48–57.
Letourneau JM, et al. Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer. Cancer. 2012;118(6):1710–7.
Goodman LR, et al. Trends of socioeconomic disparities in referral patterns for fertility preservation consultation. Hum Reprod. 2012;27(7):2076–81.
Takeuchi E, et al. Physicians’ practice of discussing fertility preservation with cancer patients and the associated attitudes and barriers. Support Care Cancer. 2017;25(4):1079–85.
Fritz R, et al. Counseling patients on reproductive aging and elective fertility preservation: a survey of obstetricians and gynecologists’ experience, approach, and knowledge. J Assist Reprod Genet. 2018;35(9):1613–21.
Practice Committee of the American Society for Reproductive Medicine and Society for Assisted Reproductive Technology. Mature oocyte cryopreservation: a guideline. Fertil Steril. 2013;99(1):37–43.
Noyes N, Porcu E, Borini A. Over 900 oocyte cryopreservation babies born with no apparent increase in congenital anomalies. Reprod Biomed Online. 2009;18(6):769–76.
Grifo JA, Noyes N. Delivery rate using cryopreserved oocytes is comparable to conventional in vitro fertilization using fresh oocytes: potential fertility preservation for female cancer patients. Fertil Steril. 2009;93(2):391–6.
Reddy J, Oktay K. Ovarian stimulation and fertility preservation with the use of aromatase inhibitors in women with breast cancer. Fertil Steril. 2012;98(6):1363–9.
Decanter C, et al. Fertility preservation by controlled ovarian hyperstimulation (COH) without letrozole in young breast cancer patients before adjuvant chemotherapy: preliminary results. Fertil Steril. 2013;100(3):S169. 8 Fertility Counseling in Routine Practice: Why, When, and How?
Moravek MB, et al. Long-term outcomes in cancer patients who did or did not pursue fertility preservation. Fertil Steril. 2018;109(2):349–55.
Devi L, Goel S. Fertility preservation through gonadal cryopreservation. Reprod Med Biol. 2016;15(4):235–51.
Kim S, et al. Ovarian tissue cryopreservation and transplantation in patients with cancer. Obstet Gynecol Sci. 2018;61(4):431–42.
Falcone T, et al. GnRH agonist for gondal protection during chemotherapy. Hum Reprod. 2015;30(12):2711–2.
Hadassa R, et al. Prevention of chemotherapy-induced ovarian damage: possible roles for hormonal and non-hormonal attenuating agents. Hum Reprod Update. 2014;20(1):759–74.
The Oncofertility Consortium. Resources: fertility preservation options for pediatric and adolescent females. Chicago: The Oncofertility Consortium; 2018.
Phillippe M, et al. Laparoscopic ovarian transposition for pelvic malignancies: indications and functional outcomes. Fertil Steril. 1998;70(5):956–60.
Save My Fertility. Provider pocket guides: fertility preservation for women diagnosed with cancer. Chicago: The Oncofertility Consortium; 2018.
Woodard TL, et al. Pathways: patient centered decision counselling for women at risk of cancer-related infertility: a protocol for a comparative effectiveness cluster randomized trial. Br Med J Open. 2018;8(2):e019994.
The Oncofertility Consortium. Oncofertility decision tool web portal: decision tools. Chicago: The Oncofertility Consortium; 2018.
The Oncofertility Consortium. Adolescent fertility values clarification tool (AFVCT). 2012 Moffitt Cancer Center. Chicago: The Oncofertility Consortium; 2018.
Gardino SL, et al. Using decision trees to enhance interdisciplinary team work: the case of oncofertility. J Assist Reprod Genet. 2010;27(5):227–31.
Quinn GP, et al. More research, more responsibility: the expansion of duty to warn in cancer patients considering fertility preservation. Am J Obstet Gynecol. 2013;209(2):98–102.
LIVESTRONG Fertility. Understand the risks, explore your options, and plan for your future. Austin: LIVESTRONG Fertility; 2013.
Woodruff TK, et al., editors. Oncofertility communication: sharing information and building relationships across disciplines. New York: Springer Science; 2014.
The Oncofertility Consortium. Resources: patient navigators. Chicago: The Oncofertility Consortium; 2018.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Campbell, S.B., Woodard, T.L. (2020). Fertility Counseling in Routine Practice: Why, When, and How?. In: Azim Jr, H., Demeestere, I., Peccatori, F. (eds) Fertility Challenges and Solutions in Women with Cancer. Springer, Cham. https://doi.org/10.1007/978-3-030-24086-8_8
Download citation
DOI: https://doi.org/10.1007/978-3-030-24086-8_8
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-24085-1
Online ISBN: 978-3-030-24086-8
eBook Packages: MedicineMedicine (R0)